Compare QUBT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUBT | XGN |
|---|---|---|
| Founded | 2001 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 64.5M |
| IPO Year | 2019 | 2014 |
| Metric | QUBT | XGN |
|---|---|---|
| Price | $6.94 | $3.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $17.00 | $9.14 |
| AVG Volume (30 Days) | ★ 8.2M | 243.0K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.93 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $682,000.00 | N/A |
| Revenue This Year | $3,210.56 | $8.06 |
| Revenue Next Year | $51.26 | $12.93 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 82.84 | N/A |
| 52 Week Low | $5.76 | $2.59 |
| 52 Week High | $25.84 | $12.23 |
| Indicator | QUBT | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 48.30 |
| Support Level | $6.18 | $2.59 |
| Resistance Level | $7.71 | $3.79 |
| Average True Range (ATR) | 0.45 | 0.21 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 49.35 | 75.00 |
Quantum Computing Inc is an integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.